AL淀粉样变性的当前治疗方法。
Current treatment of AL amyloidosis.
作者信息
Palladini Giovanni, Merlini Giampaolo
出版信息
Haematologica. 2009 Aug;94(8):1044-8. doi: 10.3324/haematol.2009.008912.
Abstract
Several effective chemotherapy regimens have been developed during the last decade significantly improving the outlook of patients with AL amyloidosis. Drs. Palladini and Merlini describe our current knowledge in the field and examine future perspectives. See related article on page 1094.
摘要
在过去十年间，已经研发出了几种有效的化疗方案，显著改善了AL淀粉样变性患者的预后。帕拉迪尼医生和梅尔利尼医生阐述了我们在该领域的现有知识，并探讨了未来前景。见第1094页的相关文章。
相似文献
1
Current treatment of AL amyloidosis.AL淀粉样变性的当前治疗方法。
Haematologica. 2009 Aug;94(8):1044-8. doi: 10.3324/haematol.2009.008912.
2
[Current treatment of AL amyloidosis].[AL淀粉样变性的当前治疗方法]
Rev Med Suisse Romande. 2000 Oct;120(10):771-5.
3
[Treatment of AL amyloidosis, current data].[AL淀粉样变性的治疗，当前数据]
Rev Med Interne. 2006 Nov;27(11):809-12. doi: 10.1016/j.revmed.2006.06.013. Epub 2006 Jul 10.
4
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.口服美法仑加地塞米松治疗可使AL淀粉样变性获得长期缓解。
Blood. 2007 Jul 15;110(2):787-8. doi: 10.1182/blood-2007-02-076034.
5
[Treatment of AL amyloidosis].[AL淀粉样变性的治疗]
Rev Med Interne. 2001 Jun;22 Suppl 1:18s-19s. doi: 10.1016/s0248-8663(01)83336-1.
6
[Therapy options in systemic AL-amyloidosis with renal involvement].[伴有肾脏受累的系统性AL型淀粉样变性的治疗选择]
Dtsch Med Wochenschr. 2000 Aug 25;125(34-35):997-1002. doi: 10.1055/s-2000-7050.
7
8
[Treatment of amyloidosis].[淀粉样变性的治疗]
Tidsskr Nor Laegeforen. 2008 Jun 12;128(12):1397-400.
9
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.100例原发性淀粉样变性患者的治疗：美法仑、泼尼松和秋水仙碱与仅用秋水仙碱的随机试验。
Am J Med. 1996 Mar;100(3):290-8. doi: 10.1016/s0002-9343(97)89487-9.
10
AL amyloidosis, a curable disease?
Amyloid. 2002 Sep;9(3):203-6. doi: 10.3109/13506120209114825.
引用本文的文献
1
Amyloid Goiter in a 57-Year-Old Woman With Chronic Kidney Disease: A Case Report.一名57岁慢性肾脏病女性患者的淀粉样变甲状腺肿：病例报告
Cureus. 2024 Aug 5;16(8):e66167. doi: 10.7759/cureus.66167. eCollection 2024 Aug.
2
Amyloidogenic light chains impair plasma cell survival.淀粉样轻链可损害浆细胞存活。
Haematologica. 2023 Dec 1;108(12):3359-3371. doi: 10.3324/haematol.2022.282484.
3
Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.轻链淀粉样变性的治疗模式和结局：阿根廷淀粉样变性报告中的机构登记。
PLoS One. 2022 Oct 27;17(10):e0274578. doi: 10.1371/journal.pone.0274578. eCollection 2022.
4
Amyloid Goiter: A Case Report and Review of the Literature.淀粉样变甲状腺肿：一例病例报告及文献综述
Saudi J Med Med Sci. 2020 May-Aug;8(2):151-155. doi: 10.4103/sjmms.sjmms_308_19. Epub 2020 Apr 17.
5
Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.患者抗体轻链中的致命淀粉样形成是由单个点突变引起的。
Elife. 2020 Mar 10;9:e52300. doi: 10.7554/eLife.52300.
6
Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.自体造血干细胞移植后免疫球蛋白轻链淀粉样变性和银屑病均完全缓解：一例报告
Medicine (Baltimore). 2018 Dec;97(50):e13589. doi: 10.1097/MD.0000000000013589.
7
Trifascicular block as primary presentation of the cardiac amyloidosis; A rare case report.三分支阻滞作为心脏淀粉样变性的主要表现：1例罕见病例报告
ARYA Atheroscler. 2018 Mar;14(2):101-104. doi: 10.22122/arya.v14i2.1676.
8
Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides.评估 D-氨基酸掺入淀粉样反应肽中的效果。
J Transl Med. 2017 Dec 11;15(1):247. doi: 10.1186/s12967-017-1351-0.
9
Primary Amyloidosis Presenting as Common Bile Duct Obstruction With Cholangitis.以胆管炎伴胆总管梗阻为表现的原发性淀粉样变性
ACG Case Rep J. 2015 Jan 16;2(2):107-9. doi: 10.14309/crj.2015.20. eCollection 2015 Jan.
10
Primary systemic amyloidosis as a real diagnostic challenge - case study.原发性系统性淀粉样变性作为一项真正的诊断挑战——病例研究
Cent Eur J Immunol. 2014;39(1):61-6. doi: 10.5114/ceji.2014.42126. Epub 2014 Apr 17.
本文引用的文献
1
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain.在AL淀粉样变性中，淀粉样蛋白的组织学消退仅在血清游离轻链正常化后出现。
Haematologica. 2009 Aug;94(8):1094-100. doi: 10.3324/haematol.2008.004119.
2
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.系统性 AL 淀粉样变性患者使用每周及每两周一次硼替佐米的研究：一项 1 期剂量递增研究结果
Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4.
3
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.一种NEDD8激活酶抑制剂作为治疗癌症的新方法。
Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884.
4
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.蛋白酶体负载与容量平衡决定了多发性骨髓瘤细胞对蛋白酶体抑制的凋亡敏感性。
Blood. 2009 Mar 26;113(13):3040-9. doi: 10.1182/blood-2008-08-172734. Epub 2009 Jan 22.
5
Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases.生物环境中的淀粉样蛋白生成：挑战蛋白质错误折叠疾病中的一个基本问题。
Curr Opin Struct Biol. 2008 Dec;18(6):771-9. doi: 10.1016/j.sbi.2008.10.001. Epub 2008 Nov 13.
6
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.采用口服美法仑、地塞米松和沙利度胺治疗晚期心脏 AL 淀粉样变性患者。
Ann Hematol. 2009 Apr;88(4):347-50. doi: 10.1007/s00277-008-0600-y. Epub 2008 Sep 9.
7
Amyloidosis: is a cure possible?淀粉样变性：有可能治愈吗？
Ann Oncol. 2008 Jun;19 Suppl 4:iv63-6. doi: 10.1093/annonc/mdn200.
8
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.脂肪组织系统性淀粉样变性蛋白质组中的淀粉样蛋白生成及相关蛋白
Mol Cell Proteomics. 2008 Aug;7(8):1570-83. doi: 10.1074/mcp.M700545-MCP200. Epub 2008 May 12.
9
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.硼替佐米对复发/难治性克隆性疾病的系统性 AL 淀粉样变性的疗效。
Haematologica. 2008 Feb;93(2):295-8. doi: 10.3324/haematol.11627.
10
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.肌钙蛋白T水平作为轻链淀粉样变性中干细胞移植的排除标准。
Leuk Lymphoma. 2008 Jan;49(1):36-41. doi: 10.1080/10428190701684518.
Zotero 插件